Comparative review shows mechanisms and efficacy of TPO-RAs in immune thrombocytopenia, suggesting personalized strategies may enhance outcomes.
TPO-RAs now represent a cornerstone of chronic ITP management and are expected to see broader use as growing evidence supports earlier and more individualized treatment strategies. Future progress will rely on personalized therapeutic strategies, informed monitoring, and AI-driven predictive tools that together may enhance remission durability and long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Andres et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: